Email Updates

You are here

Advocate Primer on Long-Acting Injectable Cabotegravir for PrEP Understanding the Initial Results of HPTN 083 & HPTN 084


April 2021

In 2020, two large-scale efficacy trials found that a long-acting injectable form of PrEP provided high levels of protection among people at risk of HIV. Long-acting injectable cabotegravir (CAB-LA) was studied and showed a substantial prevention benefit in gay men and other men who have sex with men, transgender women who have sex with men, and cisgender women.

CAB-LA, developed by ViiV Healthcare, is also being used as part of a combination of injectable antiretrovirals for HIV treatment. This document focuses on CAB-LA as PrEP, outlining what’s known and what’s next for this emerging biomedical HIV prevention strategy.

Web-friendly version also available.